1-7 of 7
Joy C. Yang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment

Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard, Leandro S. D'Abronzo, Neelu Batra, Ai-Ming Yu, Amy R. Leslie, Masuda Sharifi, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (10): 1594–1607.
https://doi.org/10.1158/1535-7163.MCT-22-0216
Published: 07 October 2022
View article titled, Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment
Open the PDF for Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment in another window
Includes: Supplementary data
Journal Articles

Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer

Jinge Zhao, Shu Ning, Wei Lou, Joy C. Yang, Cameron M. Armstrong, Alan P. Lombard, Leandro S. D'Abronzo, Christopher P. Evans, Allen C. Gao, Chengfei Liu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (8): 1708–1718.
https://doi.org/10.1158/1535-7163.MCT-20-0015
Published: 04 August 2020
View article titled, Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer
Open the PDF for Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer in another window
Journal Articles

AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer

Chengfei Liu, Joy C. Yang, Cameron M. Armstrong, Wei Lou, Liangren Liu, Xiaomin Qiu, Binhao Zou, Alan P. Lombard, Leandro S. D'Abronzo, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (10): 1875–1886.
https://doi.org/10.1158/1535-7163.MCT-18-1322
Published: 01 October 2019
View article titled, AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer
Open the PDF for AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression

Vito Cucchiara, Joy C. Yang, Chengfei Liu, Hans H. Adomat, Emma S. Tomlinson Guns, Martin E. Gleave, Allen C. Gao, Christopher P. Evans
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (10): 1811–1821.
https://doi.org/10.1158/1535-7163.MCT-18-1337
Published: 01 October 2019
View article titled, GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression
Open the PDF for GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression in another window
Includes: Supplementary data
Journal Articles

Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer

Alan P. Lombard, Liangren Liu, Vito Cucchiara, Chengfei Liu, Cameron M. Armstrong, Ruining Zhao, Joy C. Yang, Wei Lou, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (10): 2197–2205.
https://doi.org/10.1158/1535-7163.MCT-17-1269
Published: 01 October 2018
View article titled, Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer
Open the PDF for Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer in another window
Journal Articles

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer

Chengfei Liu, Cameron M. Armstrong, Wei Lou, Alan P. Lombard, Vito Cucchiara, Xinwei Gu, Joy C. Yang, Nagalakshmi Nadiminty, Chong-xian Pan, Christopher P. Evans, Allen C. Gao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (8): 1521–1530.
https://doi.org/10.1158/1535-7163.MCT-16-0912
Published: 02 August 2017
View article titled, Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer
Open the PDF for Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Effect of the Specific Src Family Kinase Inhibitor Saracatinib on Osteolytic Lesions Using the PC-3 Bone Model

Joy C. Yang, Lanfang Bai, Stanley Yap, Allen C. Gao, Hsing-Jien Kung, Christopher P. Evans
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1629–1637.
https://doi.org/10.1158/1535-7163.MCT-09-1058
Published: 09 June 2010
View article titled, Effect of the Specific Src Family Kinase Inhibitor Saracatinib on Osteolytic Lesions Using the PC-3 Bone Model
Open the PDF for Effect of the Specific Src Family Kinase Inhibitor Saracatinib on Osteolytic Lesions Using the PC-3 Bone Model in another window